NCT03071224View on ClinicalTrials.gov

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

June 9, 2021

Study Completion Date

June 9, 2021

Conditions
Alzheimer DiseaseHealthy Volunteers
Interventions
DRUG

[18F] MNI-946

Subjects will undergo PET imaging using \[18F\]MNI-946, a PET radioligand for imaging tau.

DRUG

[18F]Florbetapir

Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-946.

Trial Locations (1)

06510

Invicro, New Haven

Sponsors

Lead Sponsor

Invicro
All Listed Sponsors
lead

Invicro

OTHER